Skip to main content
First-line NSCLC treatment approved
4/19/2018

The FDA approved AstraZeneca's Tagrisso, or osimertinib, as a first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor mutations.

Full Story: